Recruiting

Testing a new eye injection to slow vision loss from macular degeneration

Plain-English translation of NCT06659445 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated June 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing a new medication called ONL1204 that is injected directly into the eye to help protect retinal cells and slow vision loss in patients with geographic atrophy (GA), a severe form of age-related macular degeneration (AMD). The medication works by blocking a process that causes eye cells to die. Researchers want to find the best dose and injection schedule to help preserve sight in people living with this blinding condition.

Geographic atrophy is one of the leading causes of vision loss and blindness worldwide, especially as people age, and there are limited treatment options available. This trial exists to see whether the medication can slow or stop the progression of vision loss in people with this serious eye condition.

Do you qualify?

You likely qualify if…

you are 55 years of age or older
you have been diagnosed with geographic atrophy associated with age-related macular degeneration in at least one eye
you have reasonable vision remaining in your affected eye(s) and normal eye pressure
you are able and willing to attend regular study visits over the course of the trial
you are willing to use effective birth control during the study and for 90 days after, if of childbearing potential
your eye lesion meets specific size and location requirements confirmed by the study team

You likely don't qualify if…

you are currently enrolled in another clinical trial or have used investigational drugs in the past 6 months
you have previously received gene therapy for your eyes
you are currently taking medications that suppress the immune system's complement proteins
you have other serious eye diseases or problems that would interfere with the study
you are unable or unwilling to commit to the study schedule and requirements

What participation looks like

Participants will receive either the new medication ONL1204 at different doses, a sham (fake) injection, or an existing approved treatment, depending on which group they are randomly assigned to. Injections will be given either every 12 weeks or every 24 weeks. Throughout the study, you will have regular eye exams, vision tests, and imaging scans to measure whether the treatment is slowing vision loss. The study will involve multiple visits over an extended period to carefully monitor your eye health and safety.

AI-generated summary from trial data · Jun 12, 2026 · Not medical advice

Testing a new eye injection to slow vision loss from macular degeneration

What is this trial?

Do you qualify?

What participation looks like

Trial locations